Omeros Co. (NASDAQ:OMER) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Omeros Co. (NASDAQ:OMER) have been assigned an average recommendation of “Moderate Buy” from the five research firms that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $22.50.

A number of equities research analysts recently commented on the company. RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Rodman & Renshaw assumed coverage on Omeros in a research report on Thursday, November 14th. They set a “buy” rating and a $9.00 price target on the stock. Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research report on Friday, January 17th.

Omeros Price Performance

NASDAQ OMER opened at $9.01 on Friday. The firm has a market cap of $522.13 million, a PE ratio of -3.90 and a beta of 2.01. Omeros has a one year low of $2.61 and a one year high of $13.60. The stock’s 50 day simple moving average is $9.65 and its 200 day simple moving average is $6.13.

Institutional Trading of Omeros

A number of institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets lifted its stake in shares of Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 7,016 shares during the period. Seros Financial LLC bought a new stake in Omeros in the fourth quarter valued at about $159,000. MML Investors Services LLC lifted its stake in Omeros by 19.2% in the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 3,000 shares during the period. SPC Financial Inc. bought a new position in Omeros during the third quarter worth about $77,000. Finally, SG Americas Securities LLC acquired a new position in shares of Omeros during the 3rd quarter worth about $80,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.